Your Trusted Partner For Clinical Research and Pharmacovigilance

Why Summits Munich: Strategic Insights on Complex Generics Development

CLINEXEL was represented by Dr. Deepa Arora, CEO, and Dr. Mukesh Kumar, CSO, at the PPM Leadership Discussion organized by Why Summits in Munich on 27–28 May 2025.

The discussion focused on strategic insights for accelerating complex generics development and approvals, with industry experts highlighting the growing importance of regulatory strategy, bioequivalence studies, and timely market access for complex generic products.

A major theme of the discussion was the critical importance of timely product approvals in ensuring the commercial success of complex generics. These products face significant challenges across:

  • Formulation development
  • Quality control
  • Bioequivalence demonstration
  • Regulatory review pathways

making both development and global market entry highly demanding.

During the discussion, Dr. Mukesh Kumar highlighted that bioequivalence studies remain one of the most critical components in complex generics development.

He discussed the strategic decision between:

  • In vitro biowaivers
  • Clinical bioequivalence trials

while evaluating factors such as:

  • Development timelines
  • Regulatory risk
  • Cost efficiency
  • Predictability of approvals

Although biowaivers may initially appear to offer faster pathways, regulatory review cycles can often introduce delays. In many cases, clinical bioequivalence trials provide a more predictable and robust approach for successful approvals and faster market access.

At CLINEXEL, our team has a strong track record of securing first-cycle approvals for clinical bioequivalence studies through carefully designed, regulatory-aligned clinical programs.

While clinical approaches may require higher initial investment, they often provide:

  • Greater regulatory reliability
  • Faster commercialization opportunities
  • Stronger long-term sustainability
  • Improved market access strategies

ultimately strengthening the overall business case for complex generics development.

CLINEXEL continues to support pharmaceutical and biotechnology companies through scientifically driven clinical research, bioequivalence expertise, regulatory strategy, and globally aligned clinical development solutions designed to accelerate approvals and improve development efficiency.